Galecto, INC

Damora Therapeutics, Inc. has successfully completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026, with ordinary shares to trade under a new CUSIP starting July 20, 2026.

Damora Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of new directors and the ratification of its independent auditor.

Damora Therapeutics announced the departure of its CFO, Lori Firmani, effective May 1, 2026, with Brian Burkavage appointed as the new principal financial and accounting officer.

Damora Therapeutics has dismissed EY Denmark and appointed Ernst & Young LLP as its new independent auditor.

Damora Therapeutics announced the appointment of Jennifer Jarrett as President and CEO, alongside significant changes to its Board of Directors.

Galecto, Inc. announced the closing of a public offering of 16,644,737 common shares at $19.00 per share, raising approximately $295.9 million in net proceeds to fund operations into Phase 3 development of DMR-001.

Damora Therapeutics, Inc. (DMRA) filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased R&D and G&A expenses, substantial cash reserves, and ongoing development of its mutCALR-targeting therapies.

Damora Therapeutics, Inc. reported its first quarter 2026 financial results, highlighting significant increases in research and development expenses and a substantial cash position following recent financings, while advancing its mutCALR-targeting drug candidates.

Galecto, Inc. reported a reduced net loss for Q3 and 9M 2025 but faces substantial doubt about its ability to continue as a going concern due to insufficient cash to fund operations beyond the next 12 months.

Galecto, Inc. reported a significantly reduced net loss for Q2 2025 and the first half of the year, driven by lower operating expenses, but disclosed substantial doubt about its ability to continue as a going concern without additional funding.

Galecto, Inc. announces its Q1 2025 financial results, highlighting a strategic focus on oncology and liver diseases with the development of GB3226 and GB1211.

Galecto, Inc. announced its Q3 2024 financial results and a strategic shift to focus on developing GB1211 and BRM-1420 after completing a strategic alternative review.

Damora Therapeutics' 2025 annual report details a strategic pivot to mutCALR MPN therapies, significant capital raises, and ongoing preclinical development amidst substantial operating losses.

Galecto's 10-K filing reveals a strategic shift towards oncology and liver diseases, alongside concerns about its ability to continue as a going concern due to recurring losses and the need for additional funding.

Galecto's 10-K filing details its capital stock structure, ongoing strategic review, and the potential for strategic transactions.

Andrew Cheng, a Director of Galecto, Inc., received 30,350 shares of common stock on August 12, 2026.

Garrett Winslow, General Counsel of Damora Therapeutics, Inc., reported transactions involving the settlement of restricted stock units and the subsequent sale of shares to cover tax obligations.

Damora Therapeutics' President and CEO, Jennifer Jarrett, acquired 500,000 restricted stock units and 1,500,000 stock options on March 30, 2026.

Damora Therapeutics' General Counsel, Garrett Winslow, was granted 250,000 stock options with an exercise price of $23.05, vesting over four years.

Damora Therapeutics Director Cameron Turtle was granted 37,313 stock options with an exercise price of $23.05, vesting monthly through March 2029.

Damora Therapeutics, Inc. Director Michael Landsittel was granted 37,313 stock options with an exercise price of $23.05, vesting through March 2029.

Galecto, Inc. is calling a special meeting to approve a redomestication to the Cayman Islands, increase authorized common stock, and establish new equity incentive plans following its Damora acquisition and $285 million financing.

Galecto, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, with voting open until June 17, 2025, covering director elections, stock issuance approval, and auditor ratification.

Galecto, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to vote on the election of directors, approval of common stock issuance upon conversion of preferred stock, and ratification of the independent auditor.

Galecto, Inc. is holding its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, and is seeking stockholder approval for a reverse stock split and other corporate governance matters.

Fairmount Funds Management LLC and its affiliates increased their beneficial ownership in Galecto, Inc. to 19.99% following the conversion of Series C Preferred Stock.

Fairmount Funds Management and its affiliates have reported a 19.99% beneficial ownership in Galecto, Inc. following the acquisition of Damora Therapeutics and a $285 million PIPE financing.

Novo Holdings A/S has fully divested its stake in Galecto, Inc., ceasing to be a beneficial owner of more than five percent of the common stock.

Novo Holdings A/S has filed an Amendment No. 4 to its Schedule 13D, reporting a reduction in its beneficial ownership of Galecto, Inc. common stock to 6.5% after selling 13,334 shares.

Novo Holdings A/S has filed an amendment to its Schedule 13D, reporting a 7.6% beneficial ownership in Galecto, Inc. after a 1-for-25 reverse stock split and an increase in outstanding shares.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 2.0% passive beneficial ownership stake in Damora Therapeutics, Inc.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported beneficial ownership of 6.27% of Damora Therapeutics, Inc. common stock as of March 31, 2026.

Paramora Holding LLC has reduced its position in Damora Therapeutics to 3.39%, falling below the 5% regulatory reporting threshold.

Paragon Therapeutics, Inc. disclosed a 3.39% beneficial ownership stake in Damora Therapeutics, Inc. via a Schedule 13G filing.

Ikarian Capital, LLC and Neil Shahrestani have filed an amended Schedule 13G, reporting a 0.6% beneficial ownership stake in Galecto, Inc.

Paramora Holding LLC has reported a 7.5% beneficial ownership stake in Galecto, Inc.'s common stock, excluding convertible preferred shares.